Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. QIAGEN N.V.
  6. News
  7. Summary
    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

QIAGEN N : Clinical Laboratory Tests Market To Demonstrate Massive Growth By 2027 Owing To Increasing Prevalence Of Chronic Diseases | Grand View Research,

05/06/2021 | 08:14am EDT

The demand for clinical laboratory tests is driven by growing investments in diagnosing target diseases such as cardiovascular disorders, tuberculosis, and diabetes as well as the COVID-19 pandemic, have created a positive outlook for the clinical laboratory tests market, as per a study by Grand View Research.

The global clinical laboratory tests market size is expected to reach USD 304.9 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 7.1% over the forecast period. Introduction of new solutions for minimizing errors and maximizing efficiency is anticipated to boost the overall market growth.

Presence of favorable reimbursement plans for laboratory tests is anticipated to positively influence the global market. According to an article published in the American Clinical Laboratory Association (ACLA), these tests are reimbursed by Medicare payees either under the Physician Fee Schedule or Clinical Laboratory Fee Schedule based on the nature of service. According to an article published in Forbes, in 2018, the new clinical lab fee schedule reduced their overall payments by 10% as compared to 2017 for tests that represent nearly two-thirds of Medicare's outlays for laboratory tests.

In addition, growing demand for early detection of several diseases is anticipated to drive the clinical laboratory tests market over the forecast period. For instance, biochips are used for preparing thousands of DNA, RNA, or protein samples that can be processed on a single chip at the same time. According to an article published in the American Clinical Laboratory Association, more than 7 billion clinical laboratory examinations are performed each year in U.S. Presence of major players such as QIAGEN, Laboratory Corporation of America Holdings, Siemens Healthcare GmbH, Quest Diagnostics Incorporated, and Abbott is expected to fuel the market growth. These companies are involved in undertaking initiatives such as product development, strategic collaborations, and regional expansion.

In November 2019, QIAGEN entered into a strategic agreement with Laboratory Corporation of America Holdings to extend its existing QIAGEN Clinical Insights license. Moreover, in August 2018, QIAGEN collaborated with SRL, Inc., Japan's largest clinical testing lab company, to prepare for the introduction of novel companion diagnostic tests along with new drug approvals.

Browse full report with Table of Content @ https://www.grandviewresearch.com/industry-analysis/clinical-laboratory-tests-market

Clinical Laboratory Tests Market Report Highlights

* In 2019, basic metabolic panel dominated the type segment owing to the increasing prevalence of lifestyle-induced diseases

* Lipid panel is projected to register a CAGR of 8.0% over the forecast period owing to rising incidences of cardiovascular disorders globally

* In 2019, hepatitis dominated the liver panel segment whereas liver cirrhosis is estimated to be the fastest-growing sub-segment over the forecast period

* Central laboratories dominated the overall market in 2019 owing to the expansion of key laboratories such as Q2 Solutions and Pharmaceutical Product Development, LLC

* Primary clinics is anticipated to register a significant CAGR of 7.6% from 2020 to 2027 owing to advancements such as portable and rapid diagnostic tests

* North America dominated the global market in 2019 owing to the increasing geriatric population and high disease prevalence

* Asia Pacific is projected to be the fastest-growing market over the forecast period owing to improving healthcare infrastructure.

Request for Sample Pages @ https://www.grandviewresearch.com/industry-analysis/clinical-laboratory-tests-market/request/rs1

Clinical Laboratory Tests Market Segmentation

Grand View Research has segmented the global clinical laboratory tests market on the basis of type, end use, and region:

Clinical Laboratory Tests Type Outlook (Revenue, USD Billion, 2016 - 2027)

* Complete blood count

* HGB/HCT

* Basic metabolic panel

* BUN creatinine tests

* Electrolytes testing

* HbA1c tests

* Comprehensive metabolic panel

* Liver panel

* Renal panel

* Lipid panel

Clinical Laboratory Tests End-use Outlook (Revenue, USD Billion, 2016 - 2027)

* Central Laboratories

* Primary Clinics

Clinical Laboratory Tests Regional Outlook (Revenue, USD Billion, 2016 - 2027)

* North America

* U.S.

* Canada

* Europe

* Germany

* The U.K.

* Spain

* Italy

* France

* Russia

* Asia Pacific

* China

* India

* Japan

* Australia

* Singapore

* South Korea

* Latin America

* Brazil

* Mexico

* Argentina

* Middle East & Africa

* Saudi Arabia

* UAE

* South Africa

Speak to Analyst @ https://www.grandviewresearch.com/inquiry/1300/ibb

About Grand View Research

Grand View Research is a market research and consulting company headquartered in San Francisco, which offers syndicated research reports, customized research reports, and consulting services to clients across a number of industries, including healthcare, materials, chemicals, energy, technology, and food and beverage, among others.

Media Contact

Company Name: Grand View Research, Inc.

Contact Person: Sherry James, Corporate Sales Specialist - U.S.A.

Email: sales@grandviewresearch.com

Phone: 1888202951

Address:Grand View Research, Inc. 201 Spear Street 1100 San Francisco, CA 94105, United States

City: San Francisco

State: California

Country: United States

Website: https://www.grandviewresearch.com/industry-analysis/clinical-laboratory-tests-market

Source: www.abnewswire.com

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
LABORATORY CORPORATION OF AMERICA HOLDINGS 0.41% 266.075 Delayed Quote.30.18%
QIAGEN N.V. 0.48% 48.43 Delayed Quote.-8.99%
All news about QIAGEN N.V.
09:10aQIAGEN NVá : DZ Bank reiterates its Neutral rating
MD
06/21QIAGEN Ná : Launches CRISPR Products for Rapid Analysis of Gene-Editing Experime..
MT
06/21QIAGEN Ná : Launches Dedicated CRISPR Products for Rapid and Simplified Analysis..
BU
06/17QIAGEN NVá : Deutsche Bank reiterates its Buy rating
MD
06/15QIAGEN Ná : Shareholder Davidson Kempner European Partners To Vote Against Chair..
MT
06/11QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/11DGAP-PVRá : QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG ..
DJ
06/11Today on Wall Street: Much ado about nothing
06/11ANALYST RECOMMENDATIONS : Brown-Forman, Casey's General Stores, GameStop, Reckit..
06/11QIAGEN NVá : Berenberg reaffirms its Buy rating
MD
More news
Financials (USD)
Sales 2021 2 265 M - -
Net income 2021 492 M - -
Net Debt 2021 887 M - -
P/E ratio 2021 22,3x
Yield 2021 -
Capitalization 10 986 M 10 986 M -
EV / Sales 2021 5,24x
EV / Sales 2022 5,20x
Nbr of Employees 5 750
Free-Float 98,2%
Chart QIAGEN N.V.
Duration : Period :
QIAGEN N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 48,10 $
Average target price 57,46 $
Spread / Average Target 19,5%
EPS Revisions
Managers and Directors
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Chief Financial Officer & Managing Director
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.-8.99%10 806
MODERNA, INC.110.72%88 392
LONZA GROUP AG16.70%53 670
IQVIA HOLDINGS INC.34.45%46 441
CELLTRION, INC.-22.42%33 607
SEAGEN INC.-10.13%28 564